Page 1

VERTEX Vertex Reports Second - Quarter 2021 Financial Results July 29 , 2021 - Product revenues of $ 1.79 billion , an 18 % increase compared to Q2 2020 - ompany raises full - year 2021 ance for product revenues to $ 7.2 to $ 7.4B - - Phase 3 study of next - in - class triple combination for CF to begin in the second half of 2021 ; multiple additional clinical milestones across the pipeline expected in the next 6 to 9 months - BOSTON -- ( BUSINESS WIRE ) -- Jul . 29 , 2021-- Vertex Pharmaceuticals Incorporated ( Nasdaq : VRTX ) today reported consolidated financial results for the second quarter ended June 30 , 2021 and raised full - year 2021 guidance for product revenues to $ 7.2 to $ 7.4B . " In the second quarter of 2021 , we saw continued , significant growth and strong business performance in our cystic fibrosis franchise . We have now secured reimbursement agreements for the triple combination in more than 15 countries outside the U.S. and started expansion into younger age groups with the U.S. approval in patients 6 to 11 years of age last month . With these advancements , we are poised to reach more patients in 2021 than previously forecasted and are therefore raising our 2021 revenue guidance . Looking forward , we continue to see significant growth ahead in CF , with more than 30,000 CF patients who may benefit from the triple combination but who are not yet treated , " said Reshma Kewalramani , M.D. , Chief Executive Officer and President of Vertex . " We also made important progress with our pipeline programs in the first half of this year . Our pipeline programs are advancing quickly , with five programs in mid- or late - stage clinical trials . We continue to see impressive clinical results with CTX001 , our most advanced program outside of CF , in which we have now dosed more than 45 patients . Our pre - commercial efforts for this program are underway , as we prepare to serve patients with sickle cell disease and beta thalassemia and address the significant market opportunity . We look forward to multiple R & D milestones and data readouts in the coming 6 to 9 months , " said Dr. Kewalramani . Second - Quarter 2021 Financial Highlights Product revenues , net TRIKAFTA / KAFTRIO SYMDEKO / SYMKEVI ORKAMBI KALYDECO GAAP operating ( loss ) income Non - GAAP operating income GAAP net income Non - GAAP net income Three Months Ended June 30 , % $ ( in millions , except per share amounts ) $ $ 1,256 $ $ $ $ 2021 $ $ 1,793 $ 1,524 134 221 ( 38 ) $ 183 $ 67 $ 811 1,029 $ $ 2020 $ 232 $ $ 918 172 203 718 874 Change 687 18 % N / A 18 % 837 ( 92 ) % 18 %